We received financing from Miyazaki Taiyo Capital Co., Ltd. (Headquarters: Miyazaki City, Miyazaki).
MabGenesis Inc.
A startup biopharmaceutical company from Miyazaki University and Fujita Medical University. Through the creation (Genesis) of innovative monoclonal antibodies (Mab), we seek to improve the health and lives of people and animals. By utilizing many years of academic research, we have succeeded in dramatically improving antibody diversity and functionality, which were the weaknesses of the phage display antibody library technology. We have established a technology to rapidly obtain new monoclonal antibodies (first-in-class) against low antigenic substances such as membrane complexes, which have been difficult to obtain until now, as well as new monoclonal antibodies with superior properties to existing antibodies (best-in-class).
